Saturday, 21 November 2026NewsWorldBusinessTech
Latest

Missouri Judge Approves $7.25 Billion Roundup Cancer Settlement

A Missouri judge on Friday approved a $7.25 billion settlement to resolve thousands of lawsuits alleging that Bayer’s Roundup weedkiller causes non-Hodgkin lymphoma.

Judge Approves $7.25 Billion Roundup Settlement

St. Louis Circuit Judge Timothy Boyer found the settlement “fair, reasonable and adequate,” rejecting objections from some attorneys who argued the proposed payouts were insufficient compared to previous awards. The nationwide class-action agreement provides a long-term claims program for individuals already diagnosed with non-Hodgkin lymphoma (NHL) and those who may receive a diagnosis in coming years.

The highest average award of $165,000 applies to an occupational claimant diagnosed before 60 with an aggressive lymphoma subtype. The lowest of $10,000 covers anyone diagnosed at 78 or older. Bayer will fund the settlement through annual payments over up to 21 years.

“The Court’s final approval is a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation,” said CEO Bill Anderson in a statement reported by AFP.

File image: Bottles of Monsanto's Roundup are seen for sale June 19, 2018 at a retail store in Glendale, California
Photo: Newsweek

Supreme Court Ruling Narrows Legal Path

The approval follows a June U.S. Supreme Court decision that narrowed the legal path for plaintiffs. The high court ruled 7-2 in John Durnell’s case that federal pesticide law preempts state-level “failure-to-warn” claims, which had served as a primary theory in litigation against Bayer and its subsidiary, Monsanto.

Christopher Seeger, a court-appointed lead attorney for plaintiffs diagnosed with NHL, described the settlement as “really the only path that most victims of Roundup will have to compensation,” according to AFP. Seeger said the settlement was negotiated before the Supreme Court’s ruling, but both parties agreed to uphold the agreement regardless of the outcome.

He said the settlement would provide class members with average awards “more than double” those received through the Feinberg settlement program in the federal multidistrict litigation. “We look forward to getting this relief into the hands of all Roundup victims as quickly as possible,” he said.

Bayer maintains that Roundup and its active ingredient, glyphosate, are safe when used as directed and that the settlement does not include an admission of liability or wrongdoing. Monsanto debuted the weed killer in the 1970s. The company has faced about 200,000 claims since acquiring Monsanto for $63bn in 2018.

Judge Approves Bayer's $7.25 Billion Roundup Cancer Claims Settlement #Shorts — World Finance News Now

The International Agency for Research on Cancer designated glyphosate a probable human carcinogen in 2015. The U.S. Environmental Protection Agency has stated the product is not likely to cause cancer in humans when used according to label instructions, WKMG reported.

Settlement Includes $600 Million for Attorneys’ Fees

Judge Boyer emphasized that delaying approval risked leaving terminally ill claimants waiting “an indeterminate number of years” for relief, The Guardian reported. The approved settlement includes $600 million for attorneys’ fees.

Bayer, founded in 1863 in Barmen as a dyestuffs partnership between Friedrich Bayer and Johann Friedrich Weskott, launched its first major product, Aspirin, in 1899. The company merged with five other German firms to form IG Farben in 1925; after Allied forces seized IG Farben’s assets following World War II for its role in the Nazi war effort, Bayer was reincorporated in 1951.

Missouri Judge Approves $7.25 Billion Roundup Cancer Settlement
Photo: ABC17NEWS

In 2016, Bayer acquired Monsanto for $63bn in what was then the largest acquisition by a German company, a deal now widely regarded as one of the worst corporate mergers in history due to the resulting Roundup litigation.

Bayer previously settled a significant portion of Roundup litigation for $10.9bn in 2020 and had set aside $16 billion to cover legal costs related to Roundup cases. The company phased out glyphosate from new versions of Roundup sold for residential markets in 2023.

Bill Dodero, Bayer’s U.S. general counsel and global litigation leader, said that the verdict “should send a strong signal” that plaintiffs “will face significant challenges” pursuing Roundup-related cancer claims in the future. Any appeals filed against the current judgment will pause further payments into the settlement fund until the challenges are resolved, Newsweek noted.